These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17886297)

  • 1. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The dopamine transporter: characterization and physiopathologic implications].
    Thibaut F; Vaugeois JM; Petit M
    Encephale; 1995; 21(6):445-51. PubMed ID: 8674469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.
    Sossi V; Dinelle K; Topping GJ; Holden JE; Doudet D; Schulzer M; Ruth TJ; Stoessl AJ; de la Fuente-Fernandez R
    J Neurochem; 2009 Apr; 109(1):85-92. PubMed ID: 19183257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
    Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
    Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers.
    Sossi V; de la Fuente-Fernández R; Nandhagopal R; Schulzer M; McKenzie J; Ruth TJ; Aasly JO; Farrer MJ; Wszolek ZK; Stoessl JA
    Mov Disord; 2010 Dec; 25(16):2717-23. PubMed ID: 20939082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging dopamine transporters in Parkinson's disease.
    Brooks DJ
    Biomark Med; 2010 Oct; 4(5):651-60. PubMed ID: 20945978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling.
    Cilia R; Ko JH; Cho SS; van Eimeren T; Marotta G; Pellecchia G; Pezzoli G; Antonini A; Strafella AP
    Neurobiol Dis; 2010 Jul; 39(1):98-104. PubMed ID: 20338240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
    Cochen V; Ribeiro MJ; Nguyen JP; Gurruchaga JM; Villafane G; Loc'h C; Defer G; Samson Y; Peschanski M; Hantraye P; Cesaro P; Remy P
    Mov Disord; 2003 Aug; 18(8):928-32. PubMed ID: 12889084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine transporter: importance in Parkinson's disease.
    Nutt JG; Carter JH; Sexton GJ
    Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
    Muramatsu S; Okuno T; Suzuki Y; Nakayama T; Kakiuchi T; Takino N; Iida A; Ono F; Terao K; Inoue N; Nakano I; Kondo Y; Tsukada H
    Synapse; 2009 Jul; 63(7):541-8. PubMed ID: 19253400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration.
    Ziebell M; Khalid U; Klein AB; Aznar S; Thomsen G; Jensen P; Knudsen GM
    Neurobiol Aging; 2012 Feb; 33(2):428.e1-5. PubMed ID: 21176997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Adams J; Stoessl J
    Brain; 2006 Apr; 129(Pt 4):1050-8. PubMed ID: 16476675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
    Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
    Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
    Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
    Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.